| Category | Details |
| Definition | High blood pressure (hypertension) is a chronic condition where blood pressure levels remain elevated, increasing the risk of cardiovascular diseases, kidney failure, and stroke. |
| Global Epidemiology | Affects an estimated 1.28 billion adults worldwide, with over 75% of cases in low- and middle-income countries. |
| Around 46% of adults with hypertension are unaware of their condition. |
| Leading risk factor for premature death globally. |
| Prevalence in Key Regions | United States: Affects approximately 122 million adults (47.7% of the adult population). |
| European Union: Prevalence of ~33% in adults, with significant variability between countries. |
| India: Over 200 million adults affected; prevalence increasing due to urbanization and lifestyle changes. |
| China: Estimated 244 million adults with hypertension. |
| Caribbean: Estimated 20–25% prevalence, equating to ~5–6 million people. |
| Medicinal Cannabis Approvals | United States (FDA): No specific approval for hypertension; research focuses on cardiovascular risk reduction. |
| European Union (EMA): Cannabinoids under investigation for their vasodilatory and anti-inflammatory effects. |
| Canada: CBD products approved for wellness; limited use in hypertension management. |
| Israel: Approved for research into cardiovascular conditions, including hypertension, since 2015. |
| South Africa: CBD approved for inflammation-related conditions in 2019; potential hypertension benefits. |
| Therapeutic Cannabinoids | CBD (Cannabidiol): Demonstrates vasodilatory effects; reduces arterial stiffness and oxidative stress. |
| THC (Tetrahydrocannabinol): Potential short-term reduction in blood pressure; psychoactive effects limit use. |
| THCV (Tetrahydrocannabivarin): Emerging evidence of blood pressure modulation and improved vascular function. |
| CBG (Cannabigerol): Early studies suggest anti-inflammatory properties beneficial for hypertension. |
| Mechanism of Action | CBD: Activates CB2 receptors, promoting vasodilation and reducing vascular inflammation. |
| THCV: Acts as a CB1 antagonist to reduce vascular resistance and improve endothelial function. |
| Cannabinoids modulate the renin-angiotensin system (RAS), which plays a key role in blood pressure regulation. |
| Key Clinical Studies | Sultan et al., 2020: CBD showed significant reductions in systolic blood pressure and arterial stiffness. |
| Jadoon et al., 2017: Demonstrated CBD’s potential in lowering resting blood pressure in healthy individuals. |
| Walsh et al., 2022: THCV improved vascular health and reduced markers of oxidative stress. |
| Hussain et al., 2021: Cannabinoids demonstrated anti-inflammatory effects beneficial for hypertension management. |
| Dosage Guidelines | CBD (Oral): Start at 5–10 mg/day; titrate up to 50–100 mg/day based on response. |
| THCV (Experimental): Early trials suggest 10–20 mg/day effective for vascular health. |
| CBG (Experimental): Preliminary studies use doses of 10–15 mg/day for cardiovascular benefits. |
| Administration Methods | Oral Capsules: Preferred for consistent and long-term management. |
| Sublingual Oils: Rapid absorption; useful for acute management. |
| Inhalation: Rarely used for hypertension; unpredictable effects on blood pressure limit its use. |
| Adverse Effects | CBD: Mild side effects like fatigue, diarrhea, appetite changes; rare liver enzyme elevation. |
| THC: Psychoactive effects include anxiety, dizziness, and potential cognitive impairment. |
| THCV: Minimal psychoactive effects; gastrointestinal discomfort in early trials. |
| Research Gaps | Long-term safety and efficacy studies of cannabinoids like THCV and CBG in hypertension management are needed. |
| Understanding interactions between cannabinoids and antihypertensive medications. |
| Opportunities in the Caribbean | Prevalence: ~5–6 million adults affected, with limited access to advanced care. |
| Clinics: Cannabinoid-focused clinics could address local healthcare needs and attract medical tourists. |
| Research Hub: Positioning the region as a leader in cannabinoid-based hypertension treatments. |
